Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses

Pediatr Blood Cancer. 2008 Mar;50(3):683-7. doi: 10.1002/pbc.21107.

Abstract

Opsoclonus-myoclonus-ataxia-syndrome (OMS) represents a rare neuroblastoma-associated paraneoplastic syndrome that commonly results in neurologic deficits despite tumor resection and immunosuppressive therapy. We describe the response of five such children to high-dose dexamethasone pulses including two patients in whom previous glucocorticoids, rituximab, and cytostatic drugs were not successful. All patients had MYCN non-amplified tumors that were detected 1 to 7 months after the onset of the OMS or ataxia. This treatment resulted in a good partial response in three and in complete remission in two patients. Our results show that dexamethasone pulses are likely to be useful for both, first-line- and salvage-therapy for OMS-patients.

Publication types

  • Case Reports
  • Clinical Trial
  • Multicenter Study

MeSH terms

  • Adrenal Gland Neoplasms / complications*
  • Adrenal Gland Neoplasms / diagnosis
  • Child, Preschool
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / therapeutic use*
  • Infant
  • Male
  • Neuroblastoma / complications*
  • Neuroblastoma / diagnosis
  • Opsoclonus-Myoclonus Syndrome / diagnosis
  • Opsoclonus-Myoclonus Syndrome / drug therapy*
  • Opsoclonus-Myoclonus Syndrome / etiology
  • Pilot Projects
  • Psychomotor Disorders / etiology
  • Remission Induction
  • Salvage Therapy

Substances

  • Immunosuppressive Agents
  • Dexamethasone